Amendment to Schedule 13G Filing for X4 Pharmaceuticals, Inc.

This filing is an amendment to a Schedule 13G filed by Morgan Stanley, Morgan Stanley Investment Management Inc., and Inception Trust, collectively referred to as the MS Reporting Units, regarding their beneficial ownership of X4 Pharmaceuticals, Inc. common stock. As of February 28, 2026, Morgan Stanley beneficially owns 10.2% of the outstanding shares, amounting to 8,884,338 shares. This represents an increase from the previous ownership percentage of 9.4%. The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer. The specific details regarding voting and dispositive powers are provided in the attached cover pages and exhibits.